Cargando…

Lower toxicity and higher efficacy: a study on a novel fully human anti-EGFR antibody

Detalles Bibliográficos
Autores principales:	Qiu, Weiyi, Wang, Shuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649478/ http://dx.doi.org/10.1186/2051-1426-3-S2-P241

Ejemplares similares

A novel fully human monoclonal antibody that neutralizes multiple human IFN-α subtypes effectively: a candidate therapy for SLE
por: Wang, Shuang, et al.
Publicado: (2015)

Fully human anti-macrophage migration inhibitory factor antibodies as potential therapeutics for sepsis and septic shock
por: Kerschbaumer, Randolf, et al.
Publicado: (2008)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
por: Qiu, Weiyi, et al.
Publicado: (2019)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

A fully human anti-CD47 blocking antibody with therapeutic potential for cancer
por: Zeng, Dadi, et al.
Publicado: (2016)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model
por: Sola, Caroline, et al.
Publicado: (2013)

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
por: Lum, Lawrence G, et al.
Publicado: (2015)

P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model
por: Kobold, S, et al.
Publicado: (2014)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

A lower bound on the number of mechanisms for discriminating fourth and higher order spatial correlations
por: Seamons, John WG, et al.
Publicado: (2015)

Development of anti-infliximab antibody is associated with reduced efficacy and infusion reaction in Behçet's disease with uveitis
por: Ishigatsubo, Y, et al.
Publicado: (2015)

In silico prediction of the neutralization range of human anti-HIV monoclonal antibodies
por: Shmelkov, E, et al.
Publicado: (2012)

HIV-1 neutralizing antibodies display dual specificity for the primary and coreceptor binding sites and preferential recognition of fully-cleaved Env
por: Li, Y, et al.
Publicado: (2012)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
por: Sasada, Tetsuro, et al.
Publicado: (2013)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Fully implicit parallel simulation of single neurons
por: Hines, Michael, et al.
Publicado: (2007)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera
por: Matsuno, H, et al.
Publicado: (2003)

An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
por: Eisenberg, RA, et al.
Publicado: (2004)

Patients with Tetralogy of Fallot have lower systolic KE in the left ventricle and higher diastolic KE in the right ventricle
por: Sjöberg, Pia, et al.
Publicado: (2016)

P121 Turnaround times for the submission of information using a novel suite of fully online patient forms
por: Teuwen, P, et al.
Publicado: (2022)

Anti-peptide antibodies in the diagnosis of malaria
por: Dean Goldring, J P, et al.
Publicado: (2010)

Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies
por: Mehta, P, et al.
Publicado: (2010)

Neutralizing anti-HIV antibodies develop in a humanized mouse model of HIV-1 infection
por: Seung, E, et al.
Publicado: (2012)

PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret(®)) in patients with severe CAPS
por: Wikén, M, et al.
Publicado: (2013)

A86 CANNABIS USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS HIGHER FOLLOWING LEGALIZATION OF CANNABIS IN CANADA AND IS ASSOCIATED WITH LOWER QUALITY OF LIFE
por: Iablokov, V, et al.
Publicado: (2023)

Fully automatic segmentation of short and long axis cine cardiac MR
por: Fradkin, Maxim, et al.
Publicado: (2009)

Characterization of patients with anti-modified citrullinated vimentin antibodies (MCVA)
por: Ruiz-Ortiz de Arrizabaleta, Estíbaliz, et al.
Publicado: (2011)

Acrolein: blocking antibody formation: pro tumor, anti-allergy
por: Roth-Walter, Franziska, et al.
Publicado: (2014)

The clinical significance of anti-CCP antibodies in Korean JRA patients
por: Kim, Kwang Nam, et al.
Publicado: (2014)

P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies
por: Gorny, MK, et al.
Publicado: (2009)

Fully-automatic synthesis of cine viability CMR images with minimal estimation error
por: Hassanein, Azza S, et al.
Publicado: (2015)

Fully automatic segmentation of heart chambers in cardiac MRI using deep learning
por: Avendi, MR, et al.
Publicado: (2016)

Toxicity of two lipid emulsions on human lymphocytes and neutrophils
por: Cury-Boaventura, M, et al.
Publicado: (2007)

Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
por: Morse, Michael, et al.
Publicado: (2013)

Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T-cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies
por: Maeda, Yasuhiuro, et al.
Publicado: (2014)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_sjomvcfrdajhcfd91tsu7ng7qg